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Abstract
Background The efficacy of antiplatelet therapies following percutaneous coronary intervention (PCI) may be affected by 
body mass index (BMI).
Methods and results This is a prespecified subgroup analysis of the GLOBAL LEADERS trial, a prospective, multicenter, 
open-label, randomized controlled trial in an all-comer population undergoing PCI, comparing the experimental strategy 
(23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy [DAPT]) with a reference regimen (12-month 
aspirin monotherapy following 12-month DAPT). A total of 15,968 patients were stratified by baseline BMI with prespeci-
fied threshold of 27 kg/m2. Of those, 6973 (43.7%) patients with a BMI < 27 kg/m2 had a higher risk of all-cause mortality at 
2 years than those with BMI ≥ 27 kg/m2 (adjusted HR 1.24, 95% CI 1.02–1.49). At 2 years, the rates of the primary endpoint 
(all-cause mortality or new Q-wave myocardial infarction) were similar between treatment strategies in either BMI group 
(pinteraction = 0.51). In acute coronary syndrome, however, the experimental strategy was associated with significant reduction 
of the primary endpoint compared to the reference strategy in patients with BMI < 27 kg/m2 (HR 0.69, 95% CI 0.51–0.94), 
but not in the ones with BMI ≥ 27 kg/m2 (pinteraction = 0.047). In chronic coronary syndrome, there was no between-group 
difference in the efficacy and safety of the two antiplatelet strategies.
Conclusions Overall, BMI did not influence the treatment effect seen with ticagrelor monotherapy; however, a beneficial 
effect of ticagrelor monotherapy was seen in ACS patients with BMI < 27 kg/m2.
Trial registration The trial has been registered with ClinicalTrials.gov, Number NCT01813435.
Masafumi Ono and Ply Chichareon contributed equally to this 
work.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0039 2-020-01604 -1) contains 
supplementary material, which is available to authorized users.
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Graphic abstract
Keywords Body mass index · Percutaneous coronary intervention · Drug-eluting stent · Dual antiplatelet therapy · 
Ticagrelor monotherapy · Acute coronary syndrome
Abbreviations
ACS  Acute coronary syndromes
BARC  Bleeding Academic Research Consortium
BMI  Body mass index
CCS  Chronic coronary syndromes
DAPT  Dual antiplatelet therapy
DES  Drug-eluting stent
MI  Myocardial infarction
PCI  Percutaneous coronary intervention
Introduction
Body mass index (BMI) is simple to calculate and con-
sequently used as an indicator of general adiposity [1]. 
Although obesity is well recognized as a major risk fac-
tor of cardiovascular disease (CVD) [2], numerous stud-
ies have demonstrated a paradoxical association between 
higher BMI and lower risk of adverse events in patients 
with established CVD, even after adjusting for confound-
ing factors. In this phenomenon, dubbed the “obesity 
paradox” [3–5], patients with lower or even normal BMI 
have a higher risk of both ischemic and bleeding events 
after percutaneous coronary intervention (PCI) compared 
to those who are overweight [6]. To date, however, no 
tailored antiplatelet strategy has been recommended for 
these patients [7].
It is recognized that the efficacy of platelet inhibition 
due to antiplatelet therapy including novel potent P2Y12 
inhibitors could be associated with a patient’s BMI 
[8]. In other words, high or low BMI could lead to an 
inappropriate balance between anti-ischemic and bleeding 
risks [9–11]. Therefore, assessment of different antiplate-
let strategies after PCI, stratified according to BMI, may 
provide additional insight into patients with a “high-risk” 
BMI.
The GLOBAL LEADERS trial compared the experi-
mental antiplatelet regimen with 23-month ticagrelor 
monotherapy, to the reference regimen of conventional 
12-month dual antiplatelet therapy (DAPT) followed by 
12-month aspirin in an all-comers PCI population [12]. 
The superiority of the experimental strategy at 2 years was 
not demonstrated in the parent trial. However, non-speci-
fied secondary analyses suggested the potential efficacy of 
this novel experimental regimen in some specific patient 
subgroups [12–15]. To unravel the complex intricacies of 
the GLOBAL LEADERS trial, the present study aims to 
investigate the clinical impact of BMI on the novel anti-
platelet strategy with ticagrelor monotherapy in patients 
undergoing PCI.
Methods
Study design
This study is a prespecified subgroup analysis of the 
GLOBAL LEADERS trial [16]. The GLOBAL LEADERS 
trial [12] is a multi-center, prospective, open-label rand-
omized controlled trial in an all-comer population with 
no restriction regarding clinical presentation, complexity 
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of the lesions or number of stents used (NCT01813435). 
Details of the study design and protocol have been 
reported elsewhere [16]. In brief, the trial randomly 
assigned patients before PCI to either (i) the experimental 
strategy with 1-month DAPT (aspirin 75–100 mg daily and 
ticagrelor 90 mg twice daily) followed by 23-month tica-
grelor 90 mg twice daily monotherapy, or (ii) the reference 
regimen with 12-month DAPT [aspirin 75–100 mg daily 
and either ticagrelor 90 mg twice daily for acute coro-
nary syndromes (ACS: unstable angina, non ST-elevation 
myocardial infarction, and ST elevation myocardial infarc-
tion) or clopidogrel 75 mg daily for chronic coronary syn-
dromes (CCS)] followed by 12-month aspirin 75–100 mg 
daily monotherapy, respectively. All target lesions were 
treated by default with biolimus A9-eluting stents (BioMa-
trix, Biosensors, Europe). The trial was approved by the 
institutional review board at each center and followed the 
ethical principles of the Declaration of Helsinki. All the 
patients gave written informed consent prior to participa-
tion in the trial.
Patients population and study endpoints
The patient’s baseline BMI was calculated as weight in 
kilograms divided by height in meters squared collected 
at the time of randomization. Patients were divided into 
two groups according to a threshold BMI of 27.0  kg/
m2, which was prespecified in the design paper [16] and 
adopted by reference to previous publications [17, 18], 
and also corresponds to the median value of BMI in the 
present population. In each BMI group, clinical, demo-
graphic, angiographic, and procedural characteristics were 
compared between patients who received the experimental 
and reference antiplatelet regimen.
The primary endpoint of this study was the composite 
of all-cause mortality and new Q-wave myocardial infarc-
tion (MI) up to 2 years. Deaths from any cause were ascer-
tained without the need for adjudication [19, 20]. Q-wave 
MI was centrally adjudicated by an independent electro-
cardiogram core lab and defined in accordance with the 
Minnesota classification (new major Q–QS wave abnor-
malities) or by the appearance of a new left bundle branch 
block in conjunction with abnormal biomarkers [21]. The 
secondary safety endpoint was major bleeding events 
according to the Bleeding Academic Research Consortium 
(BARC) criteria type 3 or 5 [22]. Additional endpoints 
included stroke (ischemic or hemorrhagic), BARC type 
2 bleeding, definite stent thrombosis according to Aca-
demic Research Consortium (ARC) definition [23], and 
the composite of all-cause mortality, any stroke, and new 
Q-wave MI [16]. The composite endpoints were analyzed 
according to time-to-first event analysis.
Statistical analysis
Continuous variables are reported as mean ± standard devia-
tions (SD) or median and interquartile range (IQR), and are 
compared using Student’s t tests or Mann–Whitney U test, 
respectively. Categorical variables are reported as percent-
ages and numbers and are compared using Chi-square or 
Fisher’s exact test as appropriate.
Association between baseline BMI as a continuous varia-
ble and adverse outcomes including the primary and second-
ary endpoint is depicted using restricted cubic spline func-
tion from the adjusted Cox regression model. Kaplan–Meier 
method is used to estimate the cumulative rates of clinical 
events and log-rank test is performed to examine the differ-
ences between groups. The effect of BMI on the outcomes 
is assessed in the unadjusted and adjusted Cox proportional 
hazards model. The clinical outcomes were compared strati-
fied according to both the prespecified threshold of 27 kg/
m2 and the World Health Organization (WHO) classifica-
tion: underweight (BMI < 18.5 kg/m2), normal weight (BMI 
18.5–24.9 kg/m2), overweight (BMI 25.0–29.9 kg/m2), and 
obesity (BMI ≥ 30 kg/m2). The covariables in the adjusted 
model are listed in Fig. 2 and Table 2, which were selected 
based on previous knowledge and literature [24, 25]. Vari-
ance inflation factor (VIF) of covariables are calculated to 
confirm the absence of multicollinearity. We also performed 
the receiver operating characteristic (ROC) analysis to detect 
the optimal cutoff value of BMI for predicting the primary 
endpoint according to the Youden index. The treatment 
effect of the experimental vs. the reference strategy between 
subgroups is estimated with an unadjusted Cox regression 
model.
Because different  P2Y12 inhibitors in the reference group 
were used depending on clinical presentation (ticagrelor for 
ACS or clopidogrel for CCS), the prespecified stratified 
analysis according to clinical presentation is performed. In 
addition, landmark analyses are reported using the prespeci-
fied time points of 1 year (at the time of the planned cessa-
tion of a  P2Y12 inhibitor in the reference strategy).
Statistical significance was considered if two-sided p 
value was less than or equal 0.05. All analyses were per-
formed in SPSS Statistics, version 26 (IBM Corp., Armonk, 
281 N.Y., USA) and R software version 3.5.1 (R Foundation 
for Statistical Computing, Vienna, Austria).
Results
A total of 15,991 patients at 130 hospitals in 18 countries 
were enrolled in the GLOBAL LEADERS trial between 
1st July 2013 and 9th November 2015; of these 23 patients 
withdrew their consent and their data were deleted from the 
database. Of the remaining 15,968 patients included in the 
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main study, baseline BMI was available in 15,966 patients 
(99.99%) (Fig. 1). The median BMI was 27.68 (interquar-
tile range 25.00–30.69) kg/m2 with 6973 (43.7%) patients 
with a BMI < 27 kg/m2 and 8993 (56.3%) patients with a 
BMI ≥ 27 kg /m2. The distribution of patients according to 
BMI is shown in Fig. 2.
Baseline characteristics
A comparison of the baseline characteristics between the 
two BMI groups is shown in Table 1. Compared to those 
with a BMI ≥ 27 kg/m2, patients with BMI < 27 kg/m2 were 
older; more likely to present with ACS; had lower preva-
lence of diabetes, hypertension, hypercholesterolemia, 
renal impairment, previous MI, and previous PCI; were 
more likely to be smokers, and had a higher prevalence of 
peripheral artery disease. Patients with a BMI < 27 kg/m2 
Fig. 1  Flowchart of the present study. Among 15,966 patients 
included in this analysis, 6973 (43.7%) had BMI < 27  kg/m2 and 
8993 patients (56.3%) had BMI ≥ 27 kg/m2. Outcomes were assessed 
between experimental strategy and reference strategy in all-comers 
population, and furthermore in each clinical presentation (ACS and 
CCS). BMI body mass index, ACS acute coronary syndrome, CCS 
chronic coronary syndrome, ASA acetylsalicylic acid
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had higher rates of PCI in the left anterior descending artery 
compared to those with a BMI ≥ 27 kg/m2. There were no 
significant differences in the rates of radial access between 
the two BMI groups.
Baseline patient characteristics were comparable and well 
balanced between the experimental and reference arms in 
each BMI group as shown in online Table 1.
Comparison of 2‑year clinical outcomes 
between BMI groups
In a univariate analysis, patients with a BMI < 27 kg/m2 had 
at 2 years follow-up a higher rate of the primary endpoint 
(4.4% vs. 3.8%, unadjusted HR 1.17, 95% CI 1.00–1.37, 
p = 0.044) and secondary safety endpoint (2.4% vs. 1.9%, 
unadjusted HR 1.27, 95% CI 1.02–1.57, p = 0.033) compared 
with those with BMI ≥ 27 kg/m2 (Table 2).
For the multivariable analysis, the VIF values of covari-
ables were all < 2.0, indicating no evidence for strong 
multicollinearity. After adjustment for potential confound-
ing factors, the risk of all-cause death at 2 years remained 
higher in patients with BMI < 27 kg/m2 than in patients 
with BMI ≥ 27 kg/m2 (3.4% vs. 2.7%, unadjusted HR 1.27, 
95% CI 1.06–1.52, p = 0.009, adjusted HR 1.24, 95% CI 
1.02–1.49, p = 0.029), but other clinical outcomes includ-
ing the primary (adjusted HR 1.14, 95% CI 0.97–1.34, 
p = 0.12) and secondary endpoint (adjusted HR 1.10, 95% 
CI 0.88–1.37, p = 0.42) were no longer significantly different 
between the two BMI groups (Table 2).
The comparison of clinical outcomes according to WHO 
classification is shown in online Table 2. After adjusting 
confounding factors, the risk of all-cause mortality at 2 years 
was significantly lower in overweight patients (HR 0.75, 95% 
CI 0.60–0.93, p = 0.010) or obese patients (HR 0.74, 95% 
CI 0.57–0.95, p = 0.020) than normal weight patients. The 
correlation between the risks for the primary or secondary 
endpoint and BMI as a continuous variable showed reverse 
J-shape curves, as shown in Fig. 2 and online Table 3. The 
ROC analysis demonstrated that 25.4 kg/m2 was the optimal 
cutoff value of BMI for predicting the primary endpoint.
Impact of BMI on antiplatelet strategy
The comparison of 2-year outcomes between the experimen-
tal and reference arms are shown in Fig. 3. At the 2-year 
follow-up, there was no statistically significant treatment 
effect on the primary endpoint of all-cause mortality or new 
Q-wave MI between the experimental and reference arm in 
patients with a BMI < 27 kg/m2 (4.9% vs. 4.0%, HR 0.82, 
95% CI 0.66–1.03, p = 0.09), or BMI ≥ 27 kg/m2 (4.0% vs. 
3.6%, HR0.91, 95% CI0.74–1.13, p = 0.39, pinteraction = 0.51). 
Similarly, there was no significant effect between the anti-
platelet strategies on the secondary endpoint of BARC 
type 3 or 5 bleeding for either BMI group (BMI < 27 kg/
m2, 2.3% vs. 2.4%, HR 0.94, 95% CI 0.69–1.28, p = 0.70, 
BMI ≥ 27 kg/m2, 1.9% vs. 1.9%, HR 0.99, 95% CI 0.73–1.34, 
p = 0.96, pinteraction = 0.81). There was no beneficial treatment 
Fig. 2  Histogram of BMI stratified by clinical presentation with 
adjusted hazard ratio for adverse events according to BMI. Blue and 
red bar graphs indicate the number of patients with BMI < 27  kg/
m2 and ≥ 27  kg/m2 in the setting of ACS, respectively. Similarly, 
sky blue and orange bar graphs indicate the number of patients with 
BMI < 27  kg/m2 and ≥ 27  kg/m2 in the setting of CCS, respectively. 
Blue curve with light blue area indicates adjusted hazard ratio with 
95% CI for composite of all-cause mortality and new Q-wave MI at 
2-year according to BMI with reference of 27 kg/m2. Red curve with 
light red area indicates adjusted hazard ratio with 95% CI for BARC 
type 3 or 5 bleeding according to BMI with reference of 27 kg/m2. 
The number of knots for the cubic spline curves were three in each 
model. Adjusted covariates for all-cause mortality or new Q-wave 
MI are age (years), sex, clinical presentation (ACS or CCS), dia-
betes mellitus, hypertension, hypercholesteremia, PVD, COPD, 
renal impairment, previous MI, previous PCI, and previous CABG. 
Adjusted covariates for BARC type 3 or 5 bleeding are age (years), 
sex, clinical presentation (ACS or CCS), diabetes mellitus, previous 
bleeding, renal impairment, anemia according to WHO classification, 
and radial access in the index procedure. BMI body mass index, ACS 
acute coronary syndromes, CCS chronic coronary syndromes, HR 
hazard ratio, CI confidence interval, MI myocardial infarction, BARC 
Bleeding Academic Research Consortium, PVD peripheral vascular 
disease, COPD chronic obstructive pulmonary disease, PCI percu-
taneous coronary intervention, CABG coronary artery bypass graft, 
WHO World Health Organization
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effect related to the experimental strategy with ticagrelor 
monotherapy with regard to other clinical outcomes at 
2 years in each BMI group (Fig. 3).
Comparison of clinical outcomes between the two 
antiplatelet strategies in each BMI group stratified 
according to their clinical presentation
Clinical outcomes stratified according to clinical 
Table 1  Comparison of clinical 
and angiographic characteristics 
between patients with 
BMI < 27 kg/m2 and ≥ 27 kg/m2
Data are presented as mean ± standard deviation or percentage (number)
* Based on creatinine-estimated GFR (eGFR) clearance of < 60 ml/min/1.73 m2, using the Modification of 
Diet in Renal Disease (MDRD) formula.
BMI body mass index, PVD peripheral vascular disease, COPD chronic obstructive pulmonary disease, MI 
myocardial infarction, STEMI ST-elevation myocardial infarction, NSTEMI Non-STEMI, PCI percutaneous 
coronary intervention, CABG coronary artery bypass graft; RCA: right coronary artery, LAD left anterior 
descending artery, LCX left circumflex artery
BMI < 27 kg/m2 BMI ≥ 27 kg/m2 p value
N = 6973/15,966 (43.7%) N = 8993/15,996 (56.3%)
Age (years) 65.6 ± 10.5 63.7 ± 10.1  < 0.001
BMI (kg/m2) 24.3 ± 2.0 31.2 ± 3.7  < 0.001
Female 23.8 (1663/6973) 22.8 (2051/8993) 0.12
Clinical presentation
 Chronic coronary syndromes 51.6 (3601/6973) 54.3 (4880/8993) 0.001
 Acute coronary syndromes
  Unstable angina 12.2 (852/6973) 13.0 (1169/8993)
  NSTEMI 21.1 (1473/6973) 21.1 (1900/8993)
  STEMI 15.0 (1047/6973) 11.6 (1044/8993)
Comorbidities
 Diabetes mellitus 18.6 (1293/6968) 30.5 (2745/8987)  < 0.001
 Insulin treated 5.3 (367/6956) 9.6 (856/8963)  < 0.001
 Hypertension 67.3 (4677/6947) 78.5 (7038/8965)  < 0.001
 Hypercholesterolemia 65.9 (4446/6751) 72.6 (6322/8712)  < 0.001
 Current smoker 28.3 (1973/6973) 24.4 (2195/8993)  < 0.001
 PVD 7.1 (488/6904) 5.8 (517/8916) 0.001
 COPD 4.8 (336/6938) 5.4 (485/8956) 0.11
 Renal  impairment* 12.3 (856/6936) 14.7 (1315/8945)  < 0.001
Medical history
 Previous bleeding 0.7 (46/6966) 0.6 (52/8979) 0.52
 Previous stroke 2.4 (167/6960) 2.8 (254/8983) 0.09
 Previous MI 22.0 (1530/6952) 24.3 (2180/8968) 0.001
 Previous PCI 30.9 (2152/6968) 34.2 (3069/8984)  < 0.001
 Previous CABG 5.8 (406/6967) 6.0 (537/8986) 0.69
Procedure
 Radial access 73.4 (5089/6931) 74.5 (6670/8950) 0.12
 Number of lesions treated 0.36
  One lesion 68.0 (4698/6913) 68.2 (6094/8930)
  Two lesions 22.8 (1575/6913) 23.1 (2066/8930)
  Three or more 9.3 (640/6913) 8.6 (770/8930)
  Average number 1.4 ± 0.8 1.4 ± 0.7 0.18
 Left main PCI 2.9 (198/6913) 2.6 (231/8930) 0.29
 RCA PCI 37.7 (2607/6913) 37.5 (3347/8930) 0.77
 LAD PCI 51.7 (3575/6913) 50.1 (4476/8930) 0.047
 LCX PCI 30.7 (2125/6913) 32.3 (2884/8930) 0.037
 Bypass graft PCI 1.4 (94/6913) 1.4 (124/8930) 0.88
 Multivessel PCI 22.9 (1583/6913) 22.3 (1991/8930) 0.37
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presentation (ACS or CCS) and BMI (< 27 or ≥ 27 kg/m2) 
are shown in Table 3.
Impact of BMI on antiplatelet strategy in the setting 
of ACS
In the patients with ACS and a BMI < 27 kg/m2, the experi-
mental antiplatelet strategy resulted in a significantly lower 
rate of the primary endpoint of all-cause mortality or new 
Q-wave MI compared to the reference arm (5.8% vs. 4.1%, 
HR0.69, 95% CI0.51–0.94, p = 0.019) with a significant 
treatment effect (pinteraction = 0.047, Table 3), which was not 
seen in those with a BMI ≥ 27 kg/m2 (3.8% vs. 3.5%, HR 
1.09, 95% CI 0.79–1.50, p = 0.60). The secondary safety 
bleeding endpoint (BARC type 3 or 5 bleeding) was numer-
ically lower in patients with ACS and a BMI < 27 kg/m2 
receiving the experimental regime; however, there was no 
significant treatment effect (2.1% vs. 3.0%, HR 0.69, 95% CI 
0.45–1.06, p = 0.09, pinteraction = 0.75) (Table 3). In patients 
with ACS and a BMI ≥ 27 kg/m2, there was no significant 
difference in the incidence of the secondary safety bleeding 
endpoint between the treatment arms (1.8% vs. 2.4%, HR 
0.76, 95% CI 0.50–1.17, p = 0.21, pinteraction = 0.75), whereas 
BARC 3 bleeding was significantly lower in the experimen-
tal arm than in the reference arm (1.5% vs. 2.4%, HR 0.62, 
95% CI 0.39–0.97, p = 0.038), yet without p value for inter-
action (pinteraction = 0.59). 
In patients with BMI < 27 kg/m2 and ACS, the observed 
lower rates of events with the experimental treatment were 
mainly driven by the lower incidence of all-cause mortality, 
BARC 3 or 5 bleeding, or BARC 2 bleeding during the first 
year after index PCI; a landmark analysis after 1 year did 
not show any treatment effect in the second year (Fig. 4 and 
Suppl. Fig. 1).
Impact of BMI on antiplatelet strategy in the setting 
of CCS
In the setting of CCS, there was no difference between 
the reference and the experimental arm regardless of BMI 
group in terms of the primary endpoint (BMI < 27 kg/
m2; 4.0% vs. 4.0%, HR 0.99, 95% CI 0.72–1.38, p = 0.98; 
BMI ≥ 27  kg/m2; 3.5% vs. 4.4%, HR 0.79, 95% CI 
0.60–1.06, p = 0.11, pinteraction = 0.31) nor the secondary 
endpoint (BMI < 27 kg/m2; 2.4% vs. 1.8%, HR 1.33, 95% 
CI 0.85–2.09, p = 0.21; BMI ≥ 27 kg/m2; 1.9% vs. 1.5%, 
HR 1.31, 95% CI 0.84–2.02, p = 0.23, pinteraction = 0.95) 
(Table 3).
Discussion
In the context of a neutral trial, all presented findings should 
be viewed strictly as hypothesis generating. Nevertheless, for 
the first time to our knowledge, we have observed a differen-
tial effect of ticagrelor monotherapy, when compared with 
ticagrelor and aspirin, in relation to baseline BMI in patients 
with ACS—a subgroup who between 31 and 365 days after 
randomization were assigned to receive either ticagrelor 
Table 2  Clinical outcomes with unadjusted and adjusted hazard ratios between patients with BMI < 27 kg/m2 and ≥ 27 kg/m2
Data are presented as number (%). Unadjusted and adjusted hazard ratios (95% confidential interval) are derived from univariate and multivari-
ate Cox regression model, respectively. Adjusted covariates for bleeding events (BARC type 3 or 5 bleeding, those components, and BARC type 
2 bleeding) are age (years), sex, clinical presentation (CCS or ACS), diabetes mellitus, previous bleeding, renal impairment, anemia according to 
WHO classification, and radial access in the index procedure. Adjusted covariates for other outcomes are age (years), sex, clinical presentation 
(CCS or ACS), diabetes mellitus, hypertension, hypercholesteremia, PVD, COPD, renal impairment, previous MI, previous PCI, and previous 
CABG
BARC Bleeding Academic Research Consortium; WHO World Health Organization; Other abbreviations as in Table 1
Outcomes at 2 years BMI < 27 kg/m2 BMI ≥ 27 kg/m2 Unadjusted 
HR; BMI < 27/
BMI ≥ 27
Adjusted HR;
BMI < 27/BMI ≥ 27
No. (%) No. (%) (95%CI) p value (95% CI) P  value
All-cause death or new Q-wave MI 310 (4.4) 343 (3.8) 1.17 (1.00–1.37) 0.044 1.14 (0.97–1.34) 0.12
 All-cause death 236 (3.4) 241 (2.7) 1.27 (1.06–1.52) 0.009 1.24 (1.02–1.49) 0.029
 New Q wave MI 80 (1.1) 106 (1.2) 0.98 (0.73–1.31) 0.88 0.94 (0.69–1.28) 0.70
All-cause death, stroke, or new Q-wave MI 366 (5.2) 412 (4.6) 1.15 (1.00–1.32) 0.051 1.13 (0.98–1.32) 0.10
 BARC 3 or 5 bleeding 164 (2.4) 168 (1.9) 1.27 (1.02–1.57) 0.030 1.10 (0.88–1.37) 0.42
 BARC 5 bleeding 20 (0.3) 26 (0.3) 1.00 (0.56–1.79) 0.99 0.74 (0.40–1.37) 0.34
 BARC 3 bleeding 153 (2.2) 156 (1.7) 1.27 (1.02–1.59) 0.033 1.12 (0.89–1.41) 0.34
 BARC 2 bleeding 338 (4.8) 447 (5.0) 0.98 (0.85–1.13) 0.79 0.92 (0.79–1.06) 0.24
Definite stent thrombosis 52 (0.7) 76 (0.8) 0.89 (0.62–1.26) 0.50 0.91 (0.63–1.31) 0.61
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alone, or in combination with aspirin by the GLOBAL 
LEADERS trial protocol [14].
In the present study, the potential beneficial effect of the 
experimental strategy was only observed in patients with 
ACS who had a BMI < 27 kg/m2, and was not seen in those 
with higher BMIs. Platelet hyper-reactivity and activation 
plays a central role in the progression of atherothrombosis 
and is the result of interactions of many adaptive responses 
to obesity: insulin resistance, inflammation, oxidative stress, 
and endothelial dysfunction [2, 26].
Although a plausible pharmacodynamic explanation 
still needs to be determined, it can be explained by some 
hypothesis. Patients with high BMI and ACS are more likely 
to have a prothrombotic state, partly linked to dysglycemia 
and proinflammatory effects of metabolic syndrome. In 
the PLATO study, the beneficial effect of potent antiplate-
let regimen with ticagrelor was mainly observed when the 
patient’s body weight was higher than the median value for 
their sex (pinteraction = 0.04) [27] In addition, the substudy of 
the PLATO trial showed that impaired fibrinolysis was an 
independent predictor of cardiovascular death and was more 
common in patients with diabetes mellitus and/or higher 
BMI [28]. In those situations, strong agonist stimulation 
such as via platelet thrombin receptors as well as via colla-
gen-mediated thromboxane A2 release could overwhelm the 
effects of potent platelet P2Y12 inhibition.
Furthermore, among obese patients, cyclo-oxygenase 
(COX) inhibition, which is achieved exclusively by aspirin, 
may play a more vital role than in non-obese patients. It has 
been demonstrated that excess adipose tissue is associated 
with an increased platelet turnover, leading to unacetylated 
COX-1 and COX-2 in newly formed platelets with subse-
quent excessive thromboxane formation [29, 30]. This is fur-
ther exacerbated by extra-platelet sources of thromboxane in 
obese patients driven by inflammatory triggers and enhanced 
lipid peroxidation, resulting in activation of platelets by a 
mechanism bypassing COX-1 acetylation or through limiting 
COX-isozyme acetylation by aspirin [29, 30]. Consequently, 
Fig. 3  Clinical outcomes at 2-year and forest plots in comparison of 
patients stratified according to BMI with threshold of 27 kg/m2. The 
squares indicate estimated hazard ratio, and the horizontal lines indi-
cate 95% CI. There was no statistically significant difference in any 
clinical outcomes between experimental strategy and reference strat-
egy in each BMI group (BMI < 27  kg/m2 or ≥ 27  kg/m2). pinteraction 
values were derived from Cox regression model. Abbreviations as in 
Fig. 2
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ticagrelor monotherapy may provide insufficient antithrom-
botic effect compared to ticagrelor plus aspirin in obese 
patients with prothrombotic states [31, 32]. In other words, 
it is possible that the balance of inhibition of platelet throm-
boxane  A2  (TXA2) release vs inhibition of prostacyclin for-
mation with standard DAPT regimens is more favorable in 
obese patients than in non-obese patients [33]. More than 
a decade ago, and before the availability of prasugrel and 
ticagrelor, high BMI was associated with stent thrombosis in 
the all-comers LEADERS trial, leading to calls for the dose 
of clopidogrel to be weight adjusted [34].
On the other hand, in patients with ACS and a 
BMI < 27 kg/m2, the potentially favorable results of tica-
grelor monotherapy compared to DAPT during the first year 
require some cautious interpretation. Previously, Leadbeater, 
et al. and Kirkby, et al. demonstrated that sufficient inhibi-
tion of the  TXA2 pathway can be achieved with the sole use 
of a strong  P2Y12 inhibitor such as prasugrel or ticagrelor 
without aspirin [35]; however, these findings were not seen 
consistently [36, 37], although, this may have been due to the 
heterogeneity of the studied populations. Whereas the pos-
sibility of a play of chance remains, our results might sug-
gest that in non-obese patients with higher responsiveness to 
 P2Y12 inhibitors [38, 39], sufficient inhibition of  TXA2 path-
way could be achieved by ticagrelor monotherapy, and add-
ing aspirin could be associated with higher risks of ischemic 
and bleeding events than in obese patients [40]. In summary, 
the BMI-adjusted antiplatelet strategy with or without aspi-
rin may be effective in ACS patients undergoing PCI, and 
the aspirin-free strategy with a potent P2Y12 inhibitor could 
be beneficial for those with a relatively low BMI.
In patients with CCS, the experimental strategy resulted 
in no significant difference in any clinical outcomes, but 
did lead to numerically higher rates of major bleeding in 
patients irrespective of their BMI group. Although Orme 
et al. reported that lower platelet activity achieved with 
ticagrelor, compared with clopidogrel, also occurred in 
patients with CCS [41], our results might suggest that the 
anti-ischemic effect of potent  P2Y12 inhibitors may not 
be required in low ischemic-risk settings such as patients 
with CCS.
Finally, in our cohort, and consistent with previous 
studies, we observed the “obesity paradox” with the 
reverse J-shape association between adverse events and 
BMI as a continuous variable [6, 42, 43]. In addition, nor-
mal weight patients had a higher risk of all-cause mortality 
Fig. 4  The 1-year landmark analysis and Kaplan–Meier curves in 
patients with ACS and either BMI < 27  kg/m2 or BMI ≥ 27  kg/m2. 
The 1-year landmark analyses of primary endpoint (all-cause mor-
tality or new Q-wave MI), all-cause mortality, and secondary safety 
endpoint (BARC type 3, or 5 bleeding) have demonstrated that the 
reduced risks of adverse events in experimental arm compared to ref-
erence arm were largely obtained at 1 year in patients with ACS and 
BMI < 27  kg/m2. However, in patients with ACS and BMI ≥ 27  kg/
m2, no treatment benefits were seen in terms of primary endpoint, all-
cause mortality, and BARC type 3 or 5 bleeding, either in the first-
year and up to 2 years from 1 year. Abbreviations as in Fig. 2
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compared with overweight or obese patients according 
to the WHO classification (Table 2). Given the fact that 
most patients with a BMI < 27 kg/m2 in this study could 
be categorized as “normal weight” in the WHO classifica-
tion (Fig. 2), our results may encourage the efficacy of the 
novel P2Y12 inhibitor monotherapy for those high-risk 
“normal weight” patients.
Limitations
The present study needs to be interpreted in light of the fol-
lowing limitations. First, the present study consists of two 
prespecified subgroup analyses of a randomized controlled 
study with multiple testing (BMI and clinical presentation). 
Because in the GLOBAL LEADERS trial two different 
 P2Y12 inhibitors are used in the reference group depend-
ing on the clinical presentation of ACS (ticagrelor) or CCS 
(clopidogrel), multiple analyses according to the clinical 
presentation have to be performed to evaluate specifically 
the treatment effect strictly. However, the results could be 
a play of chance and they should be considered as hypoth-
esis generating. Second, BMI data were only available at 
the time of randomization. BMI can change depending on 
weight gain or loss during follow-up [44]. Third, in past 
trials reporting the “obesity paradox”, the current thresh-
old of BMI (27 kg/m2) prespecified in the design paper and 
based on a recent publication [16] was not widely used and 
was higher than the optimal cutoff value of 25.4 kg/m2 for 
stratifying with the risk of the primary endpoint in this study. 
In addition, the WHO classification is somewhat different. 
Indeed, the WHO classification classified patients into four 
or six categories, resulting in lower and uneven statistical 
power among these groups. Our threshold was close to the 
median value of 27.68 kg/m2 in the current study, which 
allows uniform statistical power in each group. Fourth, in 
this trial all endpoints were site reported without a clinical 
adjudication committee for serious adverse events due to 
limited financial resources. However, the GLASSY study 
[45], which is a prespecified ancillary study of the GLOBAL 
LEADERS trial with event adjudication by an independent 
clinical event committee, confirmed the consistent results 
with those of site reported.
Conclusion
There was no overall treatment effect of experimental tica-
grelor monotherapy versus standard DAPT strategy between 
the groups with high or low baseline BMI. However, a bene-
ficial treatment effect on ischemic events (primary endpoints 
of all-cause mortality or new Q-wave MI) without trade-off 
in bleeding (BARC type 3 or 5 bleeding) of the experimen-
tal treatment with ticagrelor monotherapy was observed in 
patients presenting with ACS with BMI < 27 kg/m2, which 
was not seen in patients with BMI ≥ 27 kg/m2. Our results 
suggest the potential benefit of a novel antiplatelet mono-
therapy regimen in targeting non-obese ACS patients.
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